Compare Amgen, Inc. (AMGN) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Realty Income Corp — how do they compare? Amgen, Inc. trades at $356.83 (market cap $196.12B), while Realty Income Corp trades at $63.85 (market cap $59.04B). The key difference: Amgen, Inc. is far larger — about 3.3× Realty Income Corp's market cap, and Realty Income Corp pays the higher dividend (5.14%). Which is the better fit depends on your goals.
| AMGN | O | |
|---|---|---|
Market Cap | $196.12B | $59.04B |
Sector | Health | Real Estate |
52-Week High | $388.16 | $67.56 |
52-Week Low | $271.18 | $55.93 |
Enterprise Value | $241.41B | $88.84B |
Dividend Yield | 2.77% | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Realty Income (O) trades at $63.31, up 0.22% on the day, with a bullish technical signal from moving averages and strong support at $63. The company shows robust revenue growth, reaching $5.75B in 2025, and maintains a high gross margin of 92.54%, though it has missed recent EPS estimates. Dividend payments remain consistent at $0.27 monthly, supporting income-focused strategies.
Outlook is cautiously optimistic with a consensus price target of $67.86, offering ~7% upside. Risks include rising debt levels and interest expense, but strategic expansion into data centers and high occupancy rates provide stability. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
